Table 1.
Common namea | Official nameb | N (% of total) | Gene | Subjects with known LDL-Cc | Untreated subjectsd | ||||
---|---|---|---|---|---|---|---|---|---|
N | LDL-C | pLDL | N | LDL-C | pLDL | ||||
N543H/2393del9bp | p.Asn564His/c.2393del9 | 2299 (17.4) | LDLR | 1141 | 5.0 ± 1.5 | 88 | 724 | 4.4 ± 1.2 | 87 |
R3500Q | p.Arg3527Gln | 1653 (12.5) | APOB | 1328 | 4.9 ± 1.5 | 87 | 875 | 4.3 ± 1.1 | 84 |
1359-1 | c.1359-1 G > A | 979 (7.4) | LDLR | 478 | 6.2 ± 2.1 | 92 | 181 | 5.2 ± 1.6 | 91 |
313 + 1/2 | c.313 + 1 G > C/c.313 + 2 T > C | 844 (6.4) | LDLR | 491 | 6.2 ± 2.0 | 93 | 244 | 5.4 ± 1.4 | 92 |
W23X | p.Trp44X | 472 (3.6) | LDLR | 268 | 6.2 ± 1.8 | 93 | 132 | 5.6 ± 1.6 | 93 |
S285L | p.Ser306Leu | 466 (3.5) | LDLR | 276 | 5.1 ± 1.4 | 91 | 180 | 4.8 ± 1.3 | 91 |
E207K | p.Glu228Lys | 437 (3.3) | LDLR | 276 | 6.3 ± 2.3 | 93 | 120 | 5.3 ± 1.4 | 95 |
2.5 kb del (Cape Town-2) | c.941-?_c.1186 + ? del | 295 (2.2) | LDLR | 163 | 6.4 ± 2.4 | 94 | 74 | 5.2 ± 1.4 | 94 |
191-2 | c.191-2A > G | 271 (2.1) | LDLR | 197 | 6.4 ± 2.4 | 94 | 79 | 5.3 ± 1.3 | 94 |
G322S | p.Gly343Ser | 236 (1.8) | LDLR | 212 | 4.4 ± 1.5 | 79 | 140 | 3.9 ± 1.0 | 75 |
G186G | p.Gly207Gly | 218 (1.7) | LDLR | 246 | 5.2 ± 1.7 | 89 | 131 | 4.5 ± 1.2 | 89 |
V408M | p.Val429Met | 192 (1.5) | LDLR | 82 | 6.1 ± 1.8 | 93 | 44 | 5.4 ± 1.5 | 91 |
LDL-C levels (millimoles per litre) are expressed as mean ± standard deviation, pLDL-C mean percentile for age and gender
N number, not including index cases, LDLR low-density lipoprotein receptor, APOB apolipoprotein B, LDL-C low-density lipoprotein cholesterol
aCommon name representing numbering of the codons with initiation codon is −21 for LDLR and −27 for APOB
bOfficial name representing numbering of the codons with the initiation codon is 1 [28]
cAll subjects, identified through the screening programme, of which LDL-C was measured at the moment of genetic screening (done since 2003); for subjects on lipid-lowering medication, pre-treatment LDL-C levels were estimated with correction for treatment potency [15]
dSubjects identified through the screening programme without lipid-lowering medication at the moment of genetic testing